Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Helsinki – page 27

398 clinical trials in Helsinki, Finland across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Helsinki at a glance
398
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

398 trials in Helsinki

Open in trial search

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bay 2927088
  • Sponsor:Bayer AG

Gastrointestinal stromal tumour

Not recruiting

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Migraine

Not recruiting

Study on the Effectiveness of Fremanezumab for Preventing Migraines in Children and Teens Aged 6 to 17

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Fremanezumab
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

B-cell lymphoma refractory

Not recruiting

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Plasma cell myeloma

Not recruiting

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Autonomic nervous system imbalance+1

Not recruiting

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Prostate cancer recurrent

Not recruiting

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Gastric cancer+7

Not recruiting

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Helsinki

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development against various infectious diseases, including studies of RSV, meningococcal, and influenza vaccines in different age groups.

  • Respiratory Virus Vaccines
  • Bacterial Disease Prevention
  • Immune Response Studies

Research emphasizes safety, immunogenicity, and efficacy in diverse populations from infants to older adults.

02 Neurological Conditions

Innovative research in stroke treatment and cerebral vasculature disorders, including studies on acute ischemic stroke interventions and vasoconstriction syndrome management.

  • Stroke Therapeutics
  • Dementia Prevention
  • Vascular Disorders

Trials combine therapeutic interventions with lifestyle modifications to improve patient outcomes.

03 Metabolic Disorders

Studies addressing obesity management through novel therapeutic approaches combined with lifestyle interventions, focusing on weight-related complications.

  • Weight Management
  • Metabolic Health
  • Lifestyle Interventions

Research emphasizes comprehensive treatment strategies for metabolic health improvement.

04 Oncology Research

Advanced studies in acute myeloid leukemia treatment, investigating combination therapies for patients unsuitable for intensive chemotherapy.

  • Blood Cancer Treatments
  • Targeted Therapies
  • Novel Drug Combinations

Focusing on personalized treatment approaches for specific genetic mutations.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.